Evidence map›Paper›PMID 33972651›Full record

ArticleScientific reports2021

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs.

Mercedes Márquez-Coello, Ana Arizcorreta, María Rodríguez-Pardo, Francisco Illanes-Álvarez, Denisse Márquez, Sara Cuesta-Sancho, José-Antonio Girón-González

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mercedes Márquez-CoelloServicio de Medicina Interna y Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Universidad de Cádiz, Avda Ana de Viya s/n, 11009, Cádiz, Spain.
Ana ArizcorretaServicio de Medicina Interna y Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Universidad de Cádiz, Avda Ana de Viya s/n, 11009, Cádiz, Spain.
María Rodríguez-PardoServicio de Aparato Digestivo, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Cádiz, Spain.
Francisco Illanes-ÁlvarezServicio de Medicina Interna y Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Universidad de Cádiz, Avda Ana de Viya s/n, 11009, Cádiz, Spain.
Denisse MárquezServicio de Medicina Interna y Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Universidad de Cádiz, Avda Ana de Viya s/n, 11009, Cádiz, Spain.
Sara Cuesta-Sancho *Servicio de Medicina Interna y Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Universidad de Cádiz, Avda Ana de Viya s/n, 11009, Cádiz, Spain.
José-Antonio Girón-González *Servicio de Medicina Interna y Enfermedades Infecciosas, Facultad de Medicina, Hospital Universitario Puerta del Mar, Instituto para la Investigación e Innovación en Ciencias Biomédicas de Cádiz (INiBICA), Universidad de Cádiz, Avda Ana de Viya s/n, 11009, Cádiz, Spain. joseantonio.giron@uca.es.
Hospital Universitario Puerta del Mar · ESBiomedical Research and Innovation Institute of Cadiz · ESUniversidad de Cádiz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy controls (n = 15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-β1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of ≤ 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-β1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS > 9.5 achieved a M12 LS ≤ 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS > 9.5 achieved a LS under this cutoff point.

Indexed as

AgedAntiviral AgentsBiomarkersCase-Control StudiesCoinfectionElasticity Imaging TechniquesFemaleFollow-Up StudiesHealthy VolunteersHepatitis C, ChronicHepatocyte Growth FactorHIV InfectionsHumansLiverLiver CirrhosisMaleAntiviral AgentsBiomarkersHepatocyte Growth FactorHGF protein, humanPF4 protein, humanPlatelet Factor 4TGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID33972651
PMCPMC8110591
OpenAlexW3163600623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.